GlassScriptPhysician profile
Surabhi Amar
NPI 1083698955
$13,557.51
in general payments reported to CMS, 2019-2025
54 companies · $2,986 in 2025
The $2,986 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,243 · 2020: $532 · 2021: $1,140 · 2022: $2,445 · 2023: $2,639 · 2024: $2,572 · 2025: $2,986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,667 · Education: $948 · Long Term Medical Supply Or Device Loan: $582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,667.14 |
| Education | $947.94 |
| Long Term Medical Supply Or Device Loan | $581.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,675.50 | 2019-2025 | |
| Pfizer INC. | $1,095.01 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $962.19 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Seagen INC. | $940.92 | 2019-2025 | Tukysa, Padcev, Adcetris |
| Janssen Biotech, INC. | $757.58 | 2019-2025 | Erleada, Balversa, Akeega |
| E.R. Squibb & Sons, L.L.C. | $624.18 | 2019-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $573.69 | 2022-2025 | Imfinzi, Lynparza |
| Sobi, INC | $526.04 | 2022-2025 | |
| Amgen INC. | $439.10 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Astellas Pharma US INC | $433.64 | 2019-2025 | Xospata, Xtandi, Vyloy |
| Lilly USA, LLC | $404.13 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Athenex Pharmaceutical Division, LLC | $350.00 | 2020 | |
| Genmab U.S., INC. | $327.93 | 2023-2025 | Tivdak |
| Karyopharm Therapeutics INC. | $323.26 | 2022-2025 | Xpovio |
| Daiichi Sankyo INC. | $314.25 | 2021-2025 | Enhertu |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $291.56 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Genentech USA, INC. | $258.54 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $246.59 | 2019-2023 | |
| Celgene Corporation | $234.99 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Aveo Pharmaceuticals, INC. | $213.82 | 2021-2025 | Fotivda |
| Gilead Sciences, INC. | $210.71 | 2019-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $194.55 | 2022-2025 | Zejula, Ojjaara, Jemperli |
| Puma Biotechnology, INC. | $190.60 | 2019-2025 | |
| Genzyme Corporation | $183.32 | 2019-2023 | |
| Eisai INC. | $135.64 | 2023-2025 | |
| Kite Pharma, INC. | $125.87 | 2025 | Yescarta |
| Exelixis INC. | $105.52 | 2019-2025 | Cabometyx |
| Agios Pharmaceuticals, INC. | $103.96 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $100.48 | 2021-2023 | |
| Tersera Therapeutics LLC | $99.69 | 2022-2025 | Quzyttir, Zoladex |
| Array Biopharma INC | $98.32 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Pharmacosmos Therapeutics INC. | $91.83 | 2021-2024 | Monoferric |
| Regeneron Healthcare Solutions, INC. | $81.97 | 2020-2025 | Libtayo |
| Mirati Therapeutics, INC. | $81.09 | 2023 | Krazati |
| Sanofi-Aventis U.S. LLC | $77.99 | 2022 | |
| Abbvie INC. | $76.42 | 2019-2025 | |
| Stemline Therapeutics INC. | $76.33 | 2023-2025 | Orserdu |
| Tempus Ai, INC | $66.53 | 2024-2025 | Xt Cdx |
| Adaptive Biotechnologies Corporation | $60.72 | 2022-2025 | Clonoseq |
| Clovis Oncology, INC. | $43.25 | 2019 | |
| Rigel Pharmaceuticals, INC. | $42.91 | 2019-2021 | |
| Chiesi USA, INC. | $36.73 | 2023-2024 | Ferriprox |
| Sun Pharmaceutical Industries INC. | $33.68 | 2023-2025 | Odomzo, Yonsa |
| Iovance Biotherapeutics, INC. | $33.29 | 2025 | Amtagvi |
| Secura Bio, INC. | $32.82 | 2019 | |
| Blueprint Medicines Corporation | $26.85 | 2024 | Ayvakit |
| Coherus Oncology, INC. | $23.84 | 2022 | |
| Macrogenics, INC. | $23.24 | 2023 | |
| Spectrum Pharmaceuticals INC. | $22.11 | 2024 | Rolvedon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.40 | 2025 | |
| Emd Serono, INC. | $18.18 | 2023 | Tepmetko |
| Ipsen Biopharmaceuticals, INC | $16.37 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $16.34 | 2023 | Imbruvica |
| Takeda Pharmaceuticals U.S.A., INC. | $12.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Surabhi Amar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.